Cancer driver-passenger distinction via sporadic human and dog cancer comparison: A proof-of-principle study with colorectal cancer

Oncogene

Volumn 33, Issue 7, 2014, Pages 814-822

  Tang, J ^a   Li, Y ^a   Lyon, K ^a   Camps, J ^b   Dalton, S ^a   Ried, T ^b   Zhao, S ^a  

^a University of Georgia   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CRC driver passenger distinction; epithelial cell apicobasal polarity; genomic amplifications deletions; human dog comparison; sporadic canine CRCs

Indexed keywords

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL POLARITY; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DOGS; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HCT116 CELLS; HUMANS; MOLECULAR SEQUENCE ANNOTATION; PACLITAXEL; PILOT PROJECTS; RAB GTP-BINDING PROTEINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84894042549     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.17     Document Type: Article

References (50)

1. Haber DA, Settleman J. Cancer: drivers and passengers. Nature 2007; 446: 145-146.
2. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009; 458: 719-724.
3. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-1340.
4. Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabe RR et al. International network of cancer genome projects. Nature 2010; 464: 993-998.
5. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337.
6. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R et al. A census of human cancer genes. Nat Rev Cancer 2004; 4: 177-183.
7. Boyko AR. The domestic dog: man's best friend in the genomic era. Genome Biol 2011; 12: 216.
8. Neff MW, Rine J. A fetching model organism. Cell 2006; 124: 229-231.
9. Rowell JL, McCarthy DO, Alvarez CE. Dog models of naturally occurring cancer. Trends Mol Med 2011; 17: 380-388.
10. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005; 438: 803-819.
11. Pontius JU, Mullikin JC, Smith DR, Lindblad-Toh K, Gnerre S, Clamp M et al. Initial sequence and comparative analysis of the cat genome. Genome Res 2007; 17: 1675-1689.
12. Ji X, Zhao S. DA and Xiao-two giant and composite LTR-retrotransposon- like elements identified in the human genome. Genomics 2008; 91: 249-258.
13. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-170.
14. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-274.
15. Tang J, Le S, Sun L, Yan X, Zhang M, Macleod J et al. Copy number abnormalities in sporadic canine colorectal cancers. Genome Res 2010; 20: 341-350.
16. Youmans L, Taylor C, Shin E, Harrell A, Ellis AE, Seguin B et al. Frequent alteration of the tumor suppressor gene APC in sporadic canine colorectal cancers. PLoS One 2012; 7: e50813.
17. Camps J, Grade M, Nguyen QT, Hormann P, Becker S, Hummon AB et al. Chromosomal breakpoints in primary colon cancer cluster at sites of structural variants in the genome. Cancer Res 2008; 68: 1284-1295.
18. Igaki T, Pagliarini RA, Xu T. Loss of cell polarity drives tumor growth and invasion through JNK activation in Drosophila. Current Biol 2006; 16: 1139-1146.
19. Royer C, Lu X. Epithelial cell polarity: a major gatekeeper against cancer? Cell Death Differ 2011; 18: 1470-1477.
20. Lee M, Vasioukhin V. Cell polarity and cancer-cell and tissue polarity as a noncanonical tumor suppressor. J Cell Sci 2008; 121(Pt 8): 1141-1150.
21. Skaletsky H, Kuroda-Kawaguchi T, Minx PJ, Cordum HS, Hillier L, Brown LG et al. The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. Nature 2003; 423: 825-837.
22. Reinhardt HC, Hasskamp P, Schmedding I, Morandell S, van Vugt MA, Wang X et al. DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization. Mol Cell 2010; 40: 34-49.
23. Amann T, Hellerbrand C. GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets 2009; 13: 1411-1427.
24. Jacobson KA, Klutz AM, Tosh DK, Ivanov AA, Preti D, Baraldi PG. Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering. Handb Exp Pharmacol 2009; 193: 123-159.
25. Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci USA 2009; 106: 9435-9440.
26. Bouanene H, Miled A. Conflicting views on the molecular structure of the cancer antigen CA125/MUC16. Dis Markers 2010; 28: 385-394.
27. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39(Database issue): D945-D950.
28. Lin J, Gan CM, Zhang X, Jones S, Sjoblom T, Wood LD et al. A multidimensional analysis of genes mutated in breast and colorectal cancers. Genome Res 2007; 17: 1304-1318.
29. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4: 253-265.
30. Llovera L, Mansilla S, Portugal J. Apoptotic-like death occurs through a caspaseindependent route in colon carcinoma cells undergoing mitotic catastrophe. Cancer Lett 2012; 326: 114-121.
31. Harsay E, Schekman R. Avl9p, a member of a novel protein superfamily, functions in the late secretory pathway. Mol Biol Cell 2007; 18: 1203-1219.
32. Nafisi H, Banihashemi B, Daigle M, Albert PR. GAP1(IP4BP)/RASA3 mediates Galphai-induced inhibition of mitogen-activated protein kinase. J Biol Chem 2008; 283: 35908-35917.
33. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
34. Dehal P, Predki P, Olsen AS, Kobayashi A, Folta P, Lucas S et al. Human chromosome 19 and related regions in mouse: conservative and lineage-specific evolution. Science 2001; 293: 104-111.
35. Nelson WJ. Adaptation of core mechanisms to generate cell polarity. Nature 2003; 422: 766-774.
36. Bryant DM, Mostov KE. From cells to organs: building polarized tissue. Nat Rev Mol Cell Biol 2008; 9: 887-901.
37. Li R, Gundersen GG. Beyond polymer polarity: how the cytoskeleton builds a polarized cell. Nat Rev Mol Cell Biol 2008; 9: 860-873.
38. Iden S, Collard JG. Crosstalk between small GTPases and polarity proteins in cell polarization. Nat Rev Mol Cell Biol 2008; 9: 846-859.
39. Bachmann O, Juric M, Seidler U, Manns MP, Yu H. Basolateral ion transporters involved in colonic epithelial electrolyte absorption, anion secretion and cellular homeostasis. Acta Physiol (Oxf) 2011; 201: 33-46.
40. Belleannee C, Da Silva N, Shum WW, Brown D, Breton S. Role of purinergic signaling pathways in V-ATPase recruitment to apical membrane of acidifying epididymal clear cells. Am J Physiol Cell Physiol 2010; 298: C817-C830.
41. Barrios A, Poole RJ, Durbin L, Brennan C, Holder N, Wilson SW. Eph/Ephrin signaling regulates the mesenchymal-to-epithelial transition of the paraxial mesoderm during somite morphogenesis. Current Biol 2003; 13: 1571-1582.
42. Farabaugh SM, Micalizzi DS, Jedlicka P, Zhao R, Ford HL. Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-beta signaling, epithelial-mesenchymal transition, and cancer stem cell properties. Oncogene 31: 552-562.
43. Krais AM, Hautefeuille AH, Cros MP, Krutovskikh V, Tournier JM, Birembaut P et al. CHRNA5 as negative regulator of nicotine signaling in normal and cancer bronchial cells: effects on motility, migration and p63 expression. Carcinogenesis 2011; 32: 1388-1395.
44. Levy F, Muehlethaler K, Salvi S, Peitrequin AL, Lindholm CK, Cerottini JC et al. Ubiquitylation of a melanosomal protein by HECT-E3 ligases serves as sorting signal for lysosomal degradation. Mol Biol Cell 2005; 16: 1777-1787.
45. Lott ST, Chen N, Chandler DS, Yang Q, Wang L, Rodriguez M et al. DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. PLoS Med 2009; 6: e1000068.
46. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428.
47. Jin B, Yao B, Li JL, Fields CR, Delmas AL, Liu C et al. DNMT1 and DNMT3B modulate distinct polycomb-mediated histone modifications in colon cancer. Cancer Res 2009; 69: 7412-7421.
48. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA 2007; 104: 20007-20012.
49. Ji X, Tang J, Halberg R, Busam D, Ferriera S, Pena MM et al. Distinguishing between cancer driver and passenger gene alteration candidates via cross-species comparison: a pilot study. BMC Cancer 2010; 10: 426.
50. Beck CR, Collier P, Macfarlane C, Malig M, Kidd JM, Eichler EE et al. LINE-1 retrotransposition activity in human genomes. Cell 2010; 141: 1159-1170.